| 1. |
- Alvarez López, Laura, 1968-
(författare)
-
A língua de Camões com Iemanjá : Forma e funções da linguagem do candomblé
- 2004
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The present thesis addresses the relationship between the structure and social functions of language through the study of an Afro-Brazilian Portuguese speech community. The adopted methodological, analytical, and theoretical standpoints have their origin in linguistic anthropology, social psychology of language and discourse analysis. A set of data was collected during extensive fieldwork in Salvador (Brazil), and consists of recordings of informal conversations with and between followers of Candomblé, an Afro-Brazilian religion.Focusing on the communicative process in a specific communicative setting, the linguistic analyses illustrate the relationship between language and identity by examining theway in which expressions of African origin function as identity markers. In order to connect such Africanisms used by Candomblé followers in their everyday speech with the linguistic attitudes and ideologies found in Brazilian society throughout history, an interdisciplinary approach was called for and factors that affect the speech community’s ethnolinguistic vitality were explored. Linguistic attitudes and ideologies that have influenced group vitality were analyzed in the socio-political context (or macro-context). At the same time, the purpose was to understand communication within the sacred space of Candomblé by examining issues such as changes in linguistic forms and functions in the communicative situation (or microcontext).Apart from revealing patterns of communication in Candomblé communities, the results of the analyses show how linguistic changes such as re-Africanization are triggered by changes of attitudes in society. These changes affect speakers’ identities and language use within speech communities.
|
|
| 2. |
- Gerbitz, Armin, et al.
(författare)
-
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation : results from the randomized phase I/IIa MULTIVIR-01 study
- 2023
-
Ingår i: Frontiers in Immunology. - : Frontiers Media S.A.. - 1664-3224. ; 14
-
Tidskriftsartikel (refereegranskat)abstract
- IntroductionAllogeneic stem cell transplantation is used to cure hematologic malignancies or deficiencies of the hematopoietic system. It is associated with severe immunodeficiency of the host early after transplant and therefore early reactivation of latent herpesviruses such as CMV and EBV within the first 100 days are frequent. Small studies and case series indicated that application of herpes virus specific T cells can control and prevent disease in this patient population.MethodsWe report the results of a randomized controlled multi centre phase I/IIa study (MULTIVIR-01) using a newly developed T cell product with specificity for CMV and EBV derived from the allogeneic stem cell grafts used for transplantation. The study aimed at prevention and preemptive treatment of both viruses in patients after allogeneic stem cell transplantation targeting first infusion on day +30. Primary endpoints were acute transfusion reaction and acute-graft versus-host-disease after infusion of activated T cells.ResultsThirty-three patients were screened and 9 patients were treated with a total of 25 doses of the T cell product. We show that central manufacturing can be achieved successfully under study conditions and the product can be applied without major side effects. Overall survival, transplant related mortality, cumulative incidence of graft versus host disease and number of severe adverse events were not different between treatment and control groups. Expansion of CMV/EBV specific T cells was observed in a fraction of patients, but overall there was no difference in virus reactivation.DiscussionOur study results indicate peptide stimulated epitope specific T cells derived from stem cell grafts can be administered safely for prevention and preemptive treatment of reactivation without evidence for induction of acute graft versus host disease.Clinical trial registrationhttps://clinicaltrials.gov, identifier NCT02227641.
|
|
